News
Research highlight: an early trial of an mRNA vaccine in EBV-linked tumours
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A research highlight in Cancer Communications on 21 August 2026 summarises an early-stage trial (NCT05714748) of WGc-043, an mRNA vaccine developed by WestGene Biopharma, in patients with Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma and natural killer/T-cell lymphoma. The highlight reports disease control rates of 66.67% and 57.14% respectively and a favourable tolerability profile, and notes that EBV infects more than 90% of people worldwide and is linked to several cancers. The piece presents the findings as early clinical evidence pointing to a research direction, not as an approved treatment.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open-access research highlight (CC BY 4.0); the link goes to the PubMed record because the publisher site blocks automated access (dev-083). Our own summary, no full-text copy.